{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:01:28Z","timestamp":1791889288939,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.schres.2009.03.027","type":"journal-article","created":{"date-parts":[[2009,4,29]],"date-time":"2009-04-29T09:34:38Z","timestamp":1240997678000},"page":"70-77","source":"Crossref","is-referenced-by-count":46,"title":["Cost of treatment of schizophrenia in six European countries"],"prefix":"10.1016","volume":"111","author":[{"given":"Hans Joachim","family":"Salize","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bullenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Martinez-Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf","family":"R\u00f6ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Torres-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durk","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2009.03.027_bib1","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1002\/sim.1442","article-title":"A comparison of several regression models for analysing cost of CABG surgery","volume":"22","author":"Austin","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.schres.2009.03.027_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10198-006-0348-z","article-title":"Decision models in the evaluation of psychotropic drugs: useful tool or useless toy?","volume":"7","author":"Barbui","year":"2006","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.schres.2009.03.027_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10198-006-0347-0","article-title":"A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany","volume":"7","author":"Beard","year":"2006","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.schres.2009.03.027_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1176\/ps.2008.59.5.523","article-title":"Lessons to take home from CATIE","volume":"59","author":"Carpenter","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2009.03.027_bib5","doi-asserted-by":"crossref","first-page":"s28","DOI":"10.1192\/bjp.177.39.s28","article-title":"Client Socio-Demographic and Service Receipt Inventory\u2013European Version: development of an instrument for international research. EPSILON study 5. European psychiatric services: inputs linked to outcome domains and needs","volume":"39","author":"Chisholm","year":"2000","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib6","doi-asserted-by":"crossref","DOI":"10.1185\/03007990802507547","article-title":"Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK","author":"Davies","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2009.03.027_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10198-005-0326-x","article-title":"Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers?","volume":"7","author":"Hansen","year":"2006","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.schres.2009.03.027_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1192\/bjp.173.4.334","article-title":"Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain","volume":"173","author":"Haro","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.0902-4441.2000.t01-1-acp28-03.x","article-title":"The European Service Mapping Schedule (ESMS): development of an instrument for the description and classification of mental health services","volume":"405","author":"Johnson","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2009.03.027_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2009.03.027_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1034\/j.1600-0447.2002._10310.x","article-title":"Comparing pattrerrns and costs of schizophrenia care in five European Countries: the Epsilon Study","volume":"105","author":"Knapp","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2009.03.027_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0447.107.s416.1.x","article-title":"Financing health care in Europe: context for the Schizophrenia Outpatient Health Outcomes Study","volume":"416","author":"Knapp","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2009.03.027_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00406-008-0812-0","article-title":"Do effectiveness (\u201creal world\u201d) studies on antipsychotics tell us the real truth?","volume":"258","author":"M\u00f6ller","year":"2008","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2009.03.027_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0149-7189(83)90010-1","article-title":"Assessment of patient satisfaction: development and refinement of a service evaluation questionnaire","volume":"6","author":"Nguyen","year":"1983","journal-title":"Eval. Program Plann."},{"key":"10.1016\/j.schres.2009.03.027_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/002076409904500102","article-title":"Application and results of the Manchester Short Assessment of Quality of Life (MANSA)","volume":"45","author":"Priebe","year":"1999","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1017\/S1121189X00005728","article-title":"The impact of routine outcome measurement on treatment processes in community mental health care: approach and methods of the MECCA study","volume":"11","author":"Priebe","year":"2002","journal-title":"Epidemiol. Psichiatr. Soc."},{"key":"10.1016\/j.schres.2009.03.027_bib18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1192\/bjp.bp.107.036939","article-title":"Structured patient\u2013clinician communication and one-year outcome in community mental health care: a cluster randomised controlled trial","volume":"191","author":"Priebe","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/archpsyc.63.10.1074","article-title":"Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Rosenheck","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib20","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomised trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.169.1.42","article-title":"How expensive is the comprehensive care of schizophrenic patients in the community \u2014 a cost evaluation from a German catchment area","volume":"169","author":"Salize","year":"1996","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2009.03.027_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1600-0447.1999.tb10876.x","article-title":"Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. PSICOST Group","volume":"100","author":"Salvador-Carulla","year":"1999","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2009.03.027_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00785756","article-title":"The Camberwell Assessment of Need (CAN): comparison of assessments by staff and patients of the needs of the severely mentally ill","volume":"31","author":"Slade","year":"1996","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.schres.2009.03.027_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1034\/j.1600-0447.2003.00102.x","article-title":"Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations","volume":"107","author":"Stant","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2009.03.027_bib25","first-page":"153","article-title":"An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach","volume":"8","author":"Vazquez-Polo","year":"2005","journal-title":"J. Mental Health Policy Econ."},{"key":"10.1016\/j.schres.2009.03.027_bib26","first-page":"223","article-title":"Problems with CATIE. Phase 1: looking back\u2014what the clinician needs to know","volume":"72","author":"Washburn","year":"2008","journal-title":"Conn. Med."},{"key":"10.1016\/j.schres.2009.03.027_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/00031305.1999.10474437","article-title":"When log-normal and gamma models give different results: a case study","volume":"53","author":"Wiens","year":"1999","journal-title":"Am. Stat."},{"key":"10.1016\/j.schres.2009.03.027_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1017\/S0266462306051385","article-title":"Methodological approach for assessing the cost-effectiveness of treatments using longitudinal observational data: the SOHO study","volume":"22","author":"Windmeijer","year":"2006","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.schres.2009.03.027_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-244X-8-19","article-title":"Cost of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"8","author":"Zhu","year":"2008","journal-title":"BMC Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996409001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996409001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:50:30Z","timestamp":1710291030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996409001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":29,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0920996409001327"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2009.03.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}